Evidence map›Paper›PMID 28516997›Full record

ArticleBiomaterials science2017

Peptide and antibody ligands for renal targeting: nanomedicine strategies for kidney disease.

Jonathan Wang, Jacqueline J Masehi-Lano, Eun Ji Chung

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomaterials science, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed
8.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

50 citing papers in PubMed, 97 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Protein handling in kidney tubules.Nature reviews. Nephrology · 2025
    Review
  12. Article
  13. Review
  14. Review
  15. Prospects for gene therapy in polycystic kidney disease.Current opinion in nephrology and hypertension · 2025
    Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Jonathan WangDepartment of Biomedical Engineering, University of Southern California, Los Angeles, CA 90089, USA. eunchung@usc.edu.ORCID http://orcid.org/0000-0003-3184-2705
Jacqueline J Masehi-LanoDepartment of Biomedical Engineering, University of Southern California, Los Angeles, CA 90089, USA. eunchung@usc.edu.
Eun Ji ChungDepartment of Biomedical Engineering, University of Southern California, Los Angeles, CA 90089, USA. eunchung@usc.edu.ORCID http://orcid.org/0000-0002-7726-5555
University of Southern California · US

Funding

Multimodal Peptide Amphiphile Micelles for AtherosclerosisR00HL124279 · NHLBI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI CHUNG, EUN JI PAIGE · 2016 to 2018
$747k
NHLBI NIH HHS R00 HL124279
6 · The paper itself

Abstract

The kidney is one of the body's main filtration organs, and hence, opportunity exists for designing nanomedicine that can naturally accumulate in the kidneys for renal diseases. In addition to traditional physiochemical properties for kidney accumulation, such as size and charge, synthesized nanoparticles can be conjugated with targeting ligands which further home the nanocarriers to cell types of interest. In this review, we highlight key studies that have shown success in utilizing peptide- or antibody-based ligands in nanoparticles to target the glomerulus, podocytes, or renal tubule cells in the kidney. In addition, other ligand candidates which have shown renal affinity, but have not yet been integrated into a nanoparticle are also presented. These studies can provide insight into the design of novel clinical solutions for improved detection, prevention, and treatment of renal diseases using nanomedicine efforts.

Indexed as

Amino Acid SequenceAntibodiesHumansKidneyKidney DiseasesLigandsNanomedicinePeptidesAntibodiesLigandsPeptides

Identifiers

PMID28516997
PMCPMC5531044
OpenAlexW2611690625

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.